Rate My Professor Joseph Koopmeiners

Joseph Koopmeiners, PhD, serves as the Mayo Professor and Division Head of the Division of Biostatistics & Health Data Science in the School of Public Health at the University of Minnesota Twin Cities. He is also Scientific Co-Director of the RapidEval Program in the Center for Learning Health System Sciences. Koopmeiners holds a PhD in Biostatistics from the University of Washington (2009), an MS in Biostatistics from the University of Minnesota (2004), and a BA in Mathematics from St. John's University. A member of the Masonic Cancer Center, he develops statistical methods to address questions in cancer prevention, detection, and treatment more accurately and efficiently. His research integrates statistical methods in biomarker validation and Bayesian adaptive clinical trials, with applications in tobacco regulatory science, prostate cancer imaging, cancer research, and learning health systems. These contributions exemplify a direct connection between methodological innovation and practical biomedical and public health applications.

In recognition of his research accomplishments, leadership, and impact, Koopmeiners was awarded the 2026 Distinguished McKnight University Professorship by the University of Minnesota. He is a member of Delta Omega, the Honorary Society in Public Health, and participates in the American Statistical Association, International Biometrics Society, and Society for Clinical Trials. His scholarly influence is substantial, with over 6,430 citations documented on Google Scholar, where he is identified as Professor of Biostatistics. Notable publications include 'A randomized, controlled trial of ZMapp for Ebola virus infection' (New England Journal of Medicine, 2016), 'Randomized trial of reduced-nicotine standards for cigarettes' (New England Journal of Medicine, 2015), 'Safety and immunogenicity of a nicotine conjugate vaccine in current smokers' (Clinical Pharmacology & Therapeutics, 2005), 'Identification of seven new prostate cancer susceptibility loci through a genome-wide association study' (Nature Genetics, 2009), and 'Effect of immediate vs gradual reduction in nicotine content of cigarettes on biomarkers of smoke exposure: a randomized clinical trial' (JAMA, 2018).